Welcome to our dedicated page for Movano news (Ticker: MOVE), a resource for investors and traders seeking the latest updates and insights on Movano stock.
Movano Inc. (Nasdaq: MOVE), doing business as Movano Health, generates news at the intersection of wearable medical devices, health technology, and corporate transformation. Founded in 2018, the company develops devices such as the Evie and EvieMED rings, which are designed to bring medical-grade data into consumer and enterprise wearables. Its disclosures highlight capabilities that span physiological monitoring, women’s wellness, and proprietary RF-based sensing for cuffless blood pressure and noninvasive glucose monitoring.
News coverage of Movano frequently includes product and technology updates. The company has announced clinical study results for its wrist-worn cuffless blood pressure prototype, noting accuracy within standards recognized by the FDA for wearable, cuffless blood pressure devices and the ability to collect additional vital signs such as pulse rate, SpO2, respiration rate and ECG waveforms. It has also reported enhancements to the Evie Ring’s companion app, including new personalization and trend-tracking features, integration with Apple Health, expanded workout logging, and the introduction of EvieAI, a virtual wellness assistant built from medical journal data.
Movano’s news flow also reflects regulatory and listing developments. The company has issued multiple press releases regarding Nasdaq notifications related to bid price, periodic filing timeliness, and stockholders’ equity requirements, as well as its responses, such as engaging a new independent auditor, submitting compliance plans, and implementing a one-for-ten reverse stock split to support bid price compliance. Investors following MOVE news can track how these steps affect the company’s continued listing on the Nasdaq Capital Market.
A significant portion of recent headlines centers on strategic and transactional events. Movano’s board initiated a process to explore strategic alternatives, including a sale or merger, to maximize shareholder value. This process led to a definitive Agreement and Plan of Merger with Corvex, Inc., an AI cloud computing company specializing in GPU-accelerated infrastructure. Related announcements describe the planned all-stock combination, ownership structure expectations, concurrent financings, and the intention to rename Movano Inc. as Corvex, Inc. upon closing, with the combined company headquartered in Arlington, Virginia. Movano has also communicated that it may market for sale its current operating assets, including the EvieMED Ring and its mmWave RF technology, prior to completion of the merger.
By monitoring the MOVE news feed, readers can follow updates on Movano’s wearable health products, clinical and regulatory milestones, listing status, financing activities, and the progress of its proposed merger with Corvex. This stream of information helps investors and observers understand both the company’s health technology initiatives and its potential evolution into a public vehicle for AI infrastructure through the planned combination.
Movano (NASDAQ: MOVE) and Corvex announced an all-stock merger effective Nov 10, 2025 that will bring Corvex public via combination into a pure-play AI infrastructure platform.
Key terms: merger exchange ratio tied to a $6.25 per Movano share, Corvex and Movano raised an aggregate $40.0 million in concurrent private placements, and Corvex shareholders will receive 46.6 million shares of Movano.
Movano Health will resume marketing its medical device operations including the FDA-cleared EvieMED Ring and proprietary mmWave RF technology.
Movano Health (NASDAQ: MOVE) will implement a 1-for-10 reverse stock split effective 12:01 a.m. Eastern on October 10, 2025. Shares are expected to trade on a split-adjusted basis when markets open on October 10, 2025, and the company will continue to trade under the symbol MOVE. The new CUSIP will be 62459M305. Outstanding shares will be reduced from approximately 8.3 million to approximately 0.8 million. The Reverse Stock Split is intended to increase the bid price to regain compliance with Nasdaq minimum bid price rules. Fractional shares will be paid in cash; equity awards will receive proportionate adjustments.
Movano Health (Nasdaq: MOVE) has received a listing extension from the Nasdaq Hearings Panel to maintain its listing status. The company must meet two key conditions: file its Q1 and Q2 2025 quarterly reports by September 30, 2025, and demonstrate compliance with the $1.00 minimum bid price requirement by October 30, 2025.
To address the bid price requirement, Movano has scheduled a shareholder meeting for September 26, 2025, where stockholders will vote on a proposed reverse stock split. The company is actively working with its new auditor to complete and file the delayed quarterly reports within the extension period.
Movano Health (Nasdaq: MOVE) has received a notice of non-compliance from Nasdaq due to failing to file its Q2 2025 Form 10-Q by the August 14, 2025 deadline. The company appealed its previous delisting determination at a Nasdaq Hearing Panel on August 19, 2025, presenting a compliance plan to address both the filing requirement and the $1.00 minimum bid price requirement.
As part of its compliance efforts, Movano Health engaged RBSM LLP as its new independent registered public accounting firm on August 13, 2025. The company is currently awaiting the Panel's determination, with no guarantee that it will be granted a trading suspension stay or maintain its Nasdaq listing.
Movano Health (NASDAQ: MOVE) received a delisting determination from The Nasdaq Capital Market on July 7, 2025, due to two compliance issues: failure to maintain the minimum $1.00 per share bid price requirement and late filing of its Form 10-Q for Q1 2025.
The company plans to request a hearing before a Nasdaq Hearings Panel and will seek an extended stay of the delisting process. Due to a reverse stock split within the past year, Movano is not eligible for the standard compliance period typically granted for bid price violations.
Movano Health (MOVE) has received a notification from Nasdaq regarding non-compliance with listing rules due to its failure to file the Form 10-Q for Q1 2025 on time. The quarterly report was due on May 15, 2025. The company has until July 21, 2025 to submit a compliance plan to Nasdaq. If the plan is accepted, Movano could receive up to 180 calendar days (until November 11, 2025) to file the delayed Form 10-Q. If Nasdaq rejects the plan, Movano will have the opportunity to appeal to a Nasdaq Hearings Panel.
Movano Health (MOVE) has announced that its Board of Directors has initiated a strategic review process to explore potential options including a sale, merger, or similar transaction to maximize shareholder value. The company has engaged Aquilo Partners as financial advisor and K&L Gates LLP as legal counsel to support this process.
The company emphasized that there is no guarantee this process will result in any transaction or strategic change. Additionally, Movano disclosed that due to resource constraints, it will not be able to file its Q1 2025 Form 10-Q report on time.
Movano Health (MOVE) announced positive results from an 81-participant blood pressure clinical study for its proprietary cuffless blood pressure device. The wrist-worn prototype achieved a mean absolute difference (MAD) of 4.9 mmHg, surpassing the FDA requirement of 7 mmHg MAD for wearable devices.
The latest prototype features 12 additional mmWave antennas integrated with the company's custom IC, enabling enhanced data collection and a slimmer design. The device can also monitor vital signs including pulse rate, SpO2, respiration rate, and ECG waveforms. The IRB-approved study, conducted at Movano Health Clinical Lab, compared the prototype against a hospital-grade FDA-cleared blood pressure monitor.
With hypertension affecting over 122 million Americans and 59 million having prehypertension, Movano Health is preparing for a pivotal trial to meet FDA clinical requirements, with a consumer-oriented device expected in the coming months.
Movano Health (Nasdaq: MOVE) has announced significant updates to its Evie Ring companion app, enhancing support for women's wellness tracking. The new features, available on iOS, include Apple Health integration and expanded data visualization capabilities.
Key improvements include new 7- and 30-day trend graphs for sleep metrics from medical-grade sensors, daily basal body temperature logging, and heart rate mapping with activity state tracking. The app now offers enhanced workout tracking with manual post-workout logging and displays menstrual cycle information on the Daily Summary screen.
The Evie Ring, priced at $269 with no subscription fees, is HSA/FSA eligible and compatible with both Apple and Android devices. It's available in gold, rose gold, and silver finishes, in sizes 5-12, with an optional complimentary sizing kit.
Movano Health (MOVE) has initiated a blood pressure clinical trial featuring its new cuffless blood pressure wrist wearable. The study, scheduled for completion in the second week of February 2025, will involve at least 70 participants and compare pulse pressure waveforms against a hospital-grade device.
The enhanced wearable will monitor multiple vital signs, including pulse rate, blood oxygen saturation (SpO2), respiration rate, and ECG waveforms. This trial follows three previous studies conducted between October 2023 and November 2024, which collected data from over 60 participants of diverse demographics.
The company plans to conduct an additional 100-150 person continuous-blood pressure study using an arterial line in mid-2025, aimed at finalizing the algorithm for a future FDA pivotal trial.
FAQ
What is the current stock price of Movano (MOVE)?
What is the market cap of Movano (MOVE)?
